Glaucoma: The Treatment Options, the Cost, the Wait, and the Risks
Glaucoma is often called "the silent thief of sight" because it typically causes no symptoms until meaningful vision is already lost — which is part of why understanding your options before you need them matters so much. Unlike cataracts, glaucoma isn't fixed with a single operation; it's a lifelong condition managed with a mix of drops, laser, and sometimes surgery, aimed at protecting the vision you have rather than restoring what's gone. Here's a plain-English look at how it's treated, what it costs in the US and UK, how long NHS patients typically wait, and who faces the highest risks.
What glaucoma treatment actually involves
Glaucoma damages the optic nerve, usually (though not always) because pressure inside the eye is too high. Treatment works in stages, escalating only as needed.
Ethos Heavenly Eye drops are almost always the starting point. Ethos NAC eye drops reduce eye pressure either by cutting down how much fluid the eye produces or by helping it drain more efficiently. They're taken daily, often for life, and effectiveness is checked with regular pressure checks and visual field tests.
Laser trabeculoplasty (usually "selective" laser trabeculoplasty, or SLT) is typically the next step, and increasingly a first-line option in its own right. It's a quick, in-office procedure using a focused beam of light to improve drainage through the eye's natural filtration system. Recovery is minimal — most people are back to normal activity within a day.
Surgery comes into play when drops and laser aren't controlling pressure well enough. There are two broad categories. Traditional filtration surgery — trabeculectomy or tube shunt (drainage device) surgery — creates a new, more effective drainage pathway for fluid to leave the eye, either through a surgically created flap or a small implanted tube. These are more invasive, with several weeks of recovery and closer follow-up. Minimally invasive glaucoma surgery (MIGS) — techniques like the iStent — uses tiny incisions and micro-devices to improve drainage with a much faster recovery and fewer complications, though it generally lowers pressure less dramatically than trabeculectomy or tube shunts, and is often combined with cataract surgery when both are needed.
Which path you take depends on how advanced the glaucoma is, how well pressure is controlled, and your overall eye anatomy and health — decisions your ophthalmologist will revisit at every stage, since glaucoma management is really an ongoing relationship rather than a one-off fix.
What it costs in the US
Costs vary enormously by treatment stage.
Eye drops typically run $240 to $2,500 or more per year, depending on whether a generic is available and how many medications you need; Medicare and private insurance usually cover a meaningful portion.
SLT laser costs around $1,000 to $2,000 commercially, though Medicare reimburses only about $168 per procedure, leaving Medicare patients with a modest out-of-pocket cost of roughly $35–$70 after the Part B deductible and coinsurance. Paying entirely out of pocket without insurance typically runs $1,500 to $2,500 per eye.
Trabeculectomy and tube shunt surgery are the most expensive tier. Medicare reimburses around $933 for trabeculectomy and $1,428 for tube shunts, leaving Medicare patients with out-of-pocket costs of roughly $300–$800. With commercial insurance, expect $500 to $3,500 out of pocket depending on your plan. Paying cash without insurance, these procedures typically cost $6,000 to $15,000 per eye, bundling surgeon, facility, and anaesthesia fees.
MIGS procedures generally cost $5,000 to $6,300 when paid out of pocket, though when combined with cataract surgery (as they often are) some costs overlap with that procedure.
What it costs in the UK: NHS versus private
As with most eye conditions, glaucoma treatment on the NHS is free at the point of use, covering drops, laser treatment, and surgery once your ophthalmologist confirms it's clinically necessary. This is the route the majority of UK patients take, especially since glaucoma requires years of ongoing monitoring that would be very costly to fund privately in full.
Private glaucoma treatment in the UK is generally chosen to bypass waiting lists or to access technology not routinely offered locally. Indicative 2026 pricing:
SLT laser: around £950 per eye (or roughly £1,500 for both eyes treated in one session).
Laser iridotomy (for narrow-angle glaucoma or those at risk of angle closure): around £2,000 per eye.
MIGS (e.g. iStent): pricing is generally quoted at consultation rather than published as a flat fee, since it depends on the device and whether it's combined with cataract surgery.
Trabeculectomy: from around £4,200 per eye, with post-operative adjustments (bleb needling) an additional cost if needed.
Because glaucoma is a chronic condition, many people who go private for the initial procedure still return to NHS care, or a mix of the two, for the years of monitoring that follow.
NHS waiting times
Glaucoma waiting times are a genuinely bigger concern than for cataracts, and for a specific reason: cataract surgery is a one-off wait, but glaucoma depends on years of regular follow-up appointments to catch pressure changes before they cause permanent damage — and it's precisely this follow-up capacity that's under the most strain.
Ophthalmology as a whole is one of the highest-volume specialties in the NHS, and reporting through 2026 has flagged a specific structural problem: NHS trusts aren't required to record or publish data on follow-up waiting times the way they must for first appointments, which means glaucoma patients can slip through the gaps without it showing up in official statistics. Waiting list pressure across integrated care boards rose an estimated 10–30% during 2025, with the worst clustering reported in London and the South East. Because glaucoma is symptomless until damage is done, a delayed follow-up appointment isn't just an inconvenience — clinicians have specifically warned it carries real risk of irreversible vision loss if pressure creeps up unnoticed between checks.
Initial referral-to-first-appointment waits broadly track the same NHS-wide 18-week RTT pathway described for other elective eye care, but glaucoma patients should pay particular attention to their follow-up interval (often every few months once diagnosed) and flag it directly with their clinic or GP if an appointment is delayed, rather than assuming a gap is routine.
The risks — and why age and health conditions matter
With glaucoma, age and underlying health matter in two distinct ways: they affect your risk of developing the disease in the first place, and separately, they affect the risks of treating it.
Who's most likely to develop glaucoma: age is the single biggest factor — people over 60 are around six times more likely to develop glaucoma than younger adults. Family history raises risk four to nine times if a close relative has it. Ethnicity plays a significant role too: glaucoma is six to eight times more common, and a leading cause of blindness, among Black populations compared with white populations, while Hispanic populations see a sharp risk increase after 60 and East Asian populations face higher rates of angle-closure and normal-tension glaucoma specifically. Other contributors include high eye pressure, significant short- or long-sightedness, thin corneas, past eye injury, and long-term steroid use. This is largely why regular eye pressure checks from your 40s onward — sooner with a family history — are so often recommended, since early detection is what makes treatment effective.
Diabetes raises glaucoma risk on its own, but it also complicates treatment. Diabetic patients develop standard open-angle glaucoma more often than the general population, but diabetes can also cause a more serious form called neovascular glaucoma, where diabetic retinopathy triggers abnormal blood vessel growth that blocks the eye's drainage angle entirely. In these cases, pressure can stay uncontrolled even with drops, and because the angle is closed, laser treatment isn't an option — surgical drainage devices are often needed instead. Keeping blood sugar, blood pressure, and cholesterol well controlled measurably reduces this risk.
Surgical risks for trabeculectomy and tube shunt surgery are more significant than for cataract surgery, and this is where blood-thinning medication becomes more relevant than it is for cataracts — bleeding complications like hyphema (bleeding inside the eye) or, rarely, suprachoroidal haemorrhage are a real consideration, so your surgeon may want to review your anticoagulants beforehand rather than leave them unchanged. Other risks include hypotony (the eye pressure dropping too low, which can itself cause blurred vision or cataract formation), infection at the surgical site — glaucoma-related infections can be more aggressive than the infections seen after cataract surgery — and, for tube shunts, the device gradually eroding through the tissue covering it. MIGS procedures carry meaningfully fewer of these risks, which is part of why they're often favoured for older or frailer patients when they're expected to be effective enough, though they don't lower pressure as dramatically as traditional surgery.
None of this means older adults or people with diabetes should be wary of treatment — quite the opposite, since untreated glaucoma guarantees progressive, irreversible vision loss, while treatment (even with its risks) reliably slows or halts it. It's why ophthalmologists tailor the choice between drops, laser, MIGS, and traditional surgery so carefully to each patient's age, health conditions, and how advanced the glaucoma already is, rather than defaulting to the most aggressive option available.
The bottom line
In the US, cost depends heavily on treatment stage and insurance: drops might cost a few hundred dollars a year, SLT laser as little as $35–70 with Medicare, and major surgery anywhere from a few hundred dollars with good insurance to $15,000 uninsured. In the UK, the NHS route is free but stretched, and the real concern isn't just the initial wait but keeping up with the ongoing follow-up appointments that actually protect your vision; going private (roughly £950 for laser up to £4,200+ for trabeculectomy) buys speed and consistency rather than a fundamentally different treatment. And risk-wise, age and family history mainly determine who gets glaucoma in the first place, while diabetes and blood-thinning medication are what your surgeon will focus on most carefully when deciding how to treat it.
As with any eye condition, this is general information rather than personal medical advice — only an ophthalmologist who has examined your eyes and reviewed your health history can tell you which treatment path, and which risks, actually apply to you.
